Robert Federici, MD
Interventional Cardiology · Albuquerque, NMNPI 1053315390
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,700 of the $77,046 with a category attached, or 61.9%. 27 manufacturers reported payments, led by Abiomed at 51.5% of the total. Reporting peaked in 2021 at $23,501 and has fallen 94.7% since, to $1,240 in 2025. Among interventional cardiology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 449 payments — averaging $171.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$40K
- Boston Scientific$31K
- Medtronic$3K
- Novartis$422
- Abbott$372
- Philips North America LLC$372
- plus $2K from 21 others
What the payments were for
- Consulting fees$10,00013%
- Speaking & faculty fees$47,70062%
- Travel & lodging$6,0438%
- Food & beverage$13,30317%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 71 | $39,674 |
| Boston Scientific | 191 | $31,341 |
| Medtronic(2 entities) | 56 | $2,749 |
| Novartis | 23 | $422 |
| Abbott | 7 | $372 |
| Philips North America LLC | 14 | $372 |
| Amgen | 20 | $338 |
| Heartflow, Inc. | 2 | $311 |
| Cvrx, Inc. | 5 | $257 |
| E.r. Squibb & Sons, L.L.C. | 10 | $199 |
| Johnson & Johnson | 8 | $143 |
| Asahi Intecc USA, Inc. | 1 | $125 |
| Cardiovascular Systems Inc. | 5 | $116 |
| AstraZeneca | 7 | $107 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $97 |
| Pfizer | 5 | $80 |
| Shockwave Medical, Inc | 5 | $70 |
| Baxter Healthcare | 3 | $54 |
| GE HealthCare | 1 | $36 |
| Cardiva Medical, Inc. | 1 | $35 |
| Inari Medical, Inc. | 1 | $29 |
| Teleflex LLC | 1 | $29 |
| Surmodics, Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Merck | 1 | $17 |
| Cook Medical LLC | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$38,673
- GENERAL VASCULAR ACCESS$9,681
- GENERAL - THERAPIES$5,504
- Watchman$4,102
- CROSSBOSS$3,633
- STINGRAY$3,628
- ROTABLATOR$726
- ENDURANT IIS$656
- WATCHMAN Access System$397
- GENERAL VASCULAR INTERVENTION$324
- FFRct$311
- AMPLATZER AMULET$237
- ONYX FRONTIER$163
- Endurant$127
- GENERAL - STENTS$125
- ASAHI PTCA Guide Wire$125
- Barostim Neo System$120
- Micra$111
How this compares
$77,046 in reported general payments places this provider in the 90th percentile of 25 interventional cardiology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 97 | $75,381 |
| EliquisApixaban | 44 | $40,761 |
| XareltoRivaroxaban | 35 | $37,626 |
| EntrestoSacubitril/Valsartan | 21 | $20,429 |
| BrilintaTicagrelor | 15 | $14,002 |
| Atorvastatin Calcium | 277 | $3,973 |
| Metoprolol Succinate | 163 | $2,745 |
| Rosuvastatin Calcium | 129 | $2,334 |
| ClopidogrelClopidogrel Bisulfate | 108 | $1,760 |
| Lisinopril | 138 | $1,472 |
| Losartan Potassium | 85 | $1,062 |
| Ezetimibe | 55 | $984 |
| Spironolactone | 74 | $734 |
| Nitroglycerin | 56 | $712 |
| Bumetanide | 15 | $677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $40,76144 claims |
| Johnson & JohnsonXarelto | $143 | $37,62635 claims |
| NovartisEntresto | $422 | $20,42921 claims |
| AstraZenecaBrilinta | $107 | $14,00215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 25 interventional cardiology providers in New Mexico.
Other interventional cardiology in Albuquerque
- Mark BieniarzAlbuquerque$207K
- Raymond YauAlbuquerque$171K
- Sharif HalimAlbuquerque$22K
- Geoffrey KunzAlbuquerque$22K
- Charles KimAlbuquerque$9K
- Harvey WhiteAlbuquerque$3K
- Guilherme MarinAlbuquerque$3K
- James BlankenshipAlbuquerque$2K
- John BattyAlbuquerque$82
- Abdul KhanLas Cruces$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.